Rasagiline
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Rasagiline |
| DrugBank ID | DB01367 |
| Brand Names (EU) | Azilect |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.90% |
Approved Indication (EMA)
Azilect is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hereditary late onset Parkinson disease | 99.90% | DL |
| 2 | juvenile onset Parkinson disease 19A | 99.89% | DL |
| 3 | X-linked parkinsonism-spasticity syndrome | 99.74% | DL |
| 4 | atypical juvenile parkinsonism | 99.72% | DL |
| 5 | PLA2G6-associated neurodegeneration | 99.71% | DL |
| 6 | Rasmussen subacute encephalitis | 99.56% | DL |
| 7 | Parkinson disease | 99.40% | DL |
| 8 | parkinsonian-pyramidal syndrome | 99.34% | DL |
| 9 | myelitis | 99.32% | DL |
| 10 | paralysis agitans, juvenile, of Hunt | 99.25% | DL |
| 11 | transaldolase deficiency | 99.19% | DL |
| 12 | hemiparkinsonism-hemiatrophy syndrome | 99.15% | DL |
| 13 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 99.01% | DL |
| 14 | congenital disorder of glycosylation with defective fucosylation | 98.84% | DL |
| 15 | Lewy body dementia | 98.83% | DL |
| 16 | fructose-1,6-bisphosphatase deficiency | 98.82% | DL |
| 17 | retinal dystrophy with or without extraocular anomalies | 98.81% | DL |
| 18 | early-onset parkinsonism-intellectual disability syndrome | 98.79% | DL |
| 19 | lethal infantile mitochondrial myopathy | 98.71% | DL |
| 20 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 98.69% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.